TolC作为重组蛋白疫苗对抗福氏志贺菌的设计与表达及其在小鼠中免疫原性反应的评估
Design and expression of TolC as a recombinant protein vaccine against Shigella flexneri and evaluation of immunogenic response in mice
AI总结:
本研究利用反向疫苗学方法设计并表达TolC重组蛋白疫苗,通过免疫信息学筛选和动物实验验证,该疫苗能有效保护小鼠免受福氏志贺菌感染。
摘要:
背景:志贺菌是痢疾性腹泻的主要原因之一,这种疾病被称为志贺菌病。志贺菌病在全球范围内每年导致160,000例腹泻相关死亡,尤其是5岁以下儿童。目前尚无获许可的疫苗可预防志贺菌病,因此开发一种有效且安全的抗志贺菌疫苗仍然十分必要。反向疫苗学(RV)是一种新策略,通过评估生物体的基因组或蛋白质组来寻找新的有前景的疫苗候选物。在本研究中,通过计算机模拟研究和动物实验评估了一种设计重组抗原的免疫原性,以预测一种新的抗志贺菌免疫原性候选物。方法:第一步,从UniProtKB获取福氏志贺菌的蛋白质组,然后预测外膜蛋白和胞外蛋白。TolC作为一种外膜蛋白被选中并确认。在接下来的步骤中,通过不同的在线服务器对预选蛋白进行了跨膜结构域、同源性、保守性、抗原性、溶解性以及B细胞和T细胞表位预测的评估。结果:TolC作为一种保守的外膜蛋白,在使用不同免疫信息学工具时获得了可接受的评分,并被选为动物实验研究的免疫原性抗原。重组TolC蛋白在表达和纯化后,通过三种途径腹腔注射给予BALB/c小鼠。小鼠血清用于通过间接ELISA评估IgG1产生。免疫小鼠对2 LD50的福氏志贺菌ATCC12022表现出有效保护(攻毒研究)。结论:因此,反向疫苗学方法和实验测试结果表明,TolC作为一种新型有效且具有免疫原性的抗原,能够预防志贺菌病。
英文摘要:
Background: Shigella is one of the major cause of dysenteric diarrhea, which is known shigelosis. Shigelosis causes 160,000 deaths annually of diarrheal disease in a global scale especially children less than 5 years old. No licensed vaccine is available against shigelosis, therefore, efforts for develop an effective and safe vaccine against shigella as before needed. The reverse vaccinology (RV) is a novel strategy that evaluate genome or proteome of an organism to find a new promising vaccine candidate. In this study, immunogenicity of a designed-recombinant antigen is evaluated through the insilico studies and animal experiments to predict a new immunogenic candidate against Shigella. Methods: In the first step, proteome of shigella flexneri was obtained from UniProtKB and then the outer membrane and extracellular were predicted. TolC as an outer membrane protein was selected and confirmed. In next steps, pre-selected protein was evaluated for transmembrane domains, homology, conservation, antigenicity, solubility, and B- and T-cell prediction by different online servers. Result: TolC as a conserved outer membrane protein, using different immunoinformatics tools had acceptable scores and was selected as an immunogenic antigen for animal experimenta studies. Recombinant TolC protein after expression and purification, was administered to BALB/c mice intraperitoneally over three routes. The sera of mice was used to evaluate the IgG1 production assay by indirect-ELISA. The immunized mice depicted effective protection against 2 LD50 of shigella flexneri ATCC12022 (challenge study). Conclusion: Therefore, the reverse vaccinology approach and experimental test results demonstrated that TolC as a novel effective and immunogenic antigen is capable for protection against shigellosis.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。